The short answer
L-arginine may lower blood pressure in some settings, while lofexidine can cause low pressure or a slow pulse. Review oral L-arginine with the treatment team before use; added harm from the exact pair has not been established.
What this answer covers
Oral L-arginine supplements. Intravenous high-dose findings are not treated as equivalent to oral use.
- Supplement or preparation
- L-Arginine
- Medication ingredient
- lofexidine
The oral findings vary
One small study found a modest reduction in diastolic pressure after repeated high-dose oral L-arginine. Another found no significant blood-pressure change after a single tested oral dose. Neither studied lofexidine.
Infusion results are different
A large intravenous dose lowered pressure in the dose-and-route study, while the tested oral dose did not. That infusion effect should not be used to predict the effect of your supplement.
Your current treatment makes symptoms important
Lofexidine requires blood-pressure and pulse monitoring during opioid withdrawal treatment. Bring the L-arginine dose and other pressure-affecting products to the team. No safe combined dose or protective interval is established.
What to do if you become lightheaded
If you feel dizzy or faint, sit or lie down. The lofexidine label tells outpatients with symptoms of low blood pressure or a slow pulse to withhold a dose and contact the prescriber for guidance. Follow your treatment team’s monitoring plan; do not make a permanent abrupt stop on your own.
Evidence and practical considerations
Side effects & toxicity
Mixed oral blood-pressure findings support cautious review without demonstrating combined symptomatic hypotension.
- Exact scope
- Oral L-arginine supplements. Intravenous high-dose findings are not treated as equivalent to oral use. with Oral lofexidine for adult opioid withdrawal; label section 11 supports hydrochloride-to-active-moiety identity.
- Medication form and route
- oral supplement unless clinician-directed electrolyte correction requires another route
- Timing or duration
- Lofexidine course is symptom-guided up to 14 days; longer supplement studies do not establish acute co-use safety.
What remains uncertain
- Small studies of selected populations, different doses and durations; no lofexidine exposure.
Factors that may matter: exact preparation; blood pressure and pulse; kidney function; other medicines; baseline electrolyte status or alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults receiving treatment for opioid withdrawal symptoms.
Can cause hypotension, bradycardia, syncope and sedation. Avoid medicines lowering pulse or pressure; potentiates benzodiazepine CNS depression and is expected to potentiate other sedating drugs. Correct hypokalemia/hypomagnesemia first and monitor ECG at initiation in those patients because lofexidine prolongs QT. Abrupt discontinuation can raise blood pressure.
How this applies: RxNorm 28863 IN maps to this SPL; section 11 confirms salt-to-active-moiety identity. Applies to prescribed oral lofexidine for adult opioid withdrawal, not another alpha-2 agonist.
Does not establish supplement depletion, automatic supplementation, exact botanical interaction rates or a safe supplement spacing interval.
Source 2: randomized placebo-controlled crossover study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 middle-aged men with hypercholesterolemia.
Diastolic blood pressure was 1.9 mm Hg lower relative to placebo; several hemodynamic responses changed, but peripheral resistance did not.
How this applies: Oral blood-pressure signal supporting caution, not proof of symptomatic combined hypotension.
No lofexidine and not an orthostatic-hypotension study; high oral dose and selected population.
Source 3: placebo-controlled pharmacokinetic-pharmacodynamic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Eight healthy men.
Blood pressure and peripheral resistance fell with 30 g intravenously but were not significantly changed after 6 g orally or intravenously.
How this applies: Preserves dose and route distinctions and a relevant null oral result.
Small acute study, no lofexidine. Negative oral result cannot establish safety for chronic use or vulnerable patients.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Inspected sources applied to exact current available claim; no clinical review asserted. | |
| Research summary published |
Article revision: db5dec1286346b33
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.